Research
and Investment Prospect of Human Vaccine Industry in China, 2014-2018, mainly
studies the market, competition pattern and segmentations of human vaccine
industry in China and analyzes the industry chain, import & export and key
enterprises of human vaccine in China.
This
report analyzes the business performances of 7 key enterprises, including
Beijing Tiantan Biological Products Co., Ltd, ChongQing ZhiFei Biological
Products Co., Ltd, Walvax Biotechnology Co., Ltd, Liaoning Chengda Co., Ltd
(LCD) etc.
As
one of powerful vaccine manufacturing countries in world, China has 42 vaccine
manufacturers with approval license. In 2013, the total of lot release quantity
of vaccines was about 755 million doses, increasing by 0.53% over the 751
million doses in 2012. Vaccine manufacturers mainly consist of state-owned enterprises,
private enterprises and foreign-funded enterprises in China.
View Full Report with TOC @ http://www.radiantinsights.com/research/research-and-investment-prospect-of-human-vaccine-industry-in-china
Seeing
from the lot release quantity of vaccine in 2013, the state-owned enterprises
still take the leading position in vaccine market, with market shares of 62%,
followed by private enterprises and foreign-funded enterprises successively,
with market shares of 33.77% and 4.23% respectively.
Most
of market of typeⅠvaccines
is still dominated by state-owned enterprises, including 6 largest institutes
of China National Biotec-Group Company Limited and Changchun Keygen Biological
Products Co., Ltd. Private enterprises take half of market shares of typeⅡvaccines,
the representative enterprises include: ChongQing ZhiFei Biological Products
Co., Ltd, and Walvax Biotechnology Co., Ltd etc.
While
the international enterprises have definite advantages in respects of high-end
vaccines and multivalent vaccines, taking pneumococcal vaccines for instance,
only one conjugate vaccine is available, say: Pneumococcal 7-Valent Conjugate
Vaccine produced by Pfizer. Although, at present, several enterprises are
conducting studies on pneumococcal conjugate vaccines, it is still long to
launch on the market, with huge uncertainties.
In
2014-2018, the average growth rate of vaccine in China will maintain at 16%-18%.
The main driving factors include: implement of national vaccine immunization
plan, increasing receptivity of vaccine by people, rising trend of initiative
vaccination and increase of type Ⅱvaccines
application etc. It can be expected that the market scale of vaccine will hit
CNY 40.5 billion in 2018.
About Us
Radiant Insights is a platform for companies looking to meet their
market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Blog
URL: http://sagarkadam.kinja.com/
No comments:
Post a Comment